Skip to main content
An official website of the United States government

autologous tumor infiltrating lymphocytes ITIL-168

A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patient's digested and cryopreserved tumor, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs ITIL-168 specifically recognize and kill the patient's tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous TILs ITIL-168
Code name:ITIL 168
ITIL-168
ITIL168
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search